Cargando…

Assessment of Antidiabetic Activity of the Shikonin by Allosteric Inhibition of Protein-Tyrosine Phosphatase 1B (PTP1B) Using State of Art: An In Silico and In Vitro Tactics

Diabetes mellitus is a multifactorial disease that affects both developing and developed countries and is a major public health concern. Many synthetic drugs are available in the market, which counteracts the associated pathologies. However, due to the propensity of side effects, there is an unmet n...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeed, Mohd, Shoaib, Ambreen, Tasleem, Munazzah, Alabdallah, Nadiyah M., Alam, Md Jahoor, Asmar, Zeina El, Jamal, Qazi Mohammad Sajid, Bardakci, Fevzi, Alqahtani, Saad S., Ansari, Irfan Ahmad, Badraoui, Riadh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271486/
https://www.ncbi.nlm.nih.gov/pubmed/34208908
http://dx.doi.org/10.3390/molecules26133996
_version_ 1783721013562834944
author Saeed, Mohd
Shoaib, Ambreen
Tasleem, Munazzah
Alabdallah, Nadiyah M.
Alam, Md Jahoor
Asmar, Zeina El
Jamal, Qazi Mohammad Sajid
Bardakci, Fevzi
Alqahtani, Saad S.
Ansari, Irfan Ahmad
Badraoui, Riadh
author_facet Saeed, Mohd
Shoaib, Ambreen
Tasleem, Munazzah
Alabdallah, Nadiyah M.
Alam, Md Jahoor
Asmar, Zeina El
Jamal, Qazi Mohammad Sajid
Bardakci, Fevzi
Alqahtani, Saad S.
Ansari, Irfan Ahmad
Badraoui, Riadh
author_sort Saeed, Mohd
collection PubMed
description Diabetes mellitus is a multifactorial disease that affects both developing and developed countries and is a major public health concern. Many synthetic drugs are available in the market, which counteracts the associated pathologies. However, due to the propensity of side effects, there is an unmet need for the investigation of safe and effective drugs. This research aims to find a novel phytoconstituent having diminished action on blood glucose levels with the least side effects. Shikonin is a naturally occurring naphthoquinone dying pigment obtained by the roots of the Boraginaceae family. Besides its use as pigments, it can be used as an antimicrobial, anti-inflammatory, and anti-tumor agent. This research aimed to hypothesize the physicochemical and phytochemical properties of Shikonin’s in silico interaction with protein tyrosine phosphate 1B, as well as it’s in vitro studies, in order to determine its potential anti-diabetic impact. To do so, molecular docking experiments with target proteins were conducted to assess their anti-diabetic ability. Analyzing associations with corresponding amino acids revealed the significant molecular interactions between Shikonin and diabetes-related target proteins. In silico pharmacokinetics and toxicity profile of Shikonin using ADMET Descriptor, Toxicity Prediction, and Calculate Molecular Properties tools from Biovia Discovery Studio v4.5. Filter by Lipinski and Veber Rule’s module from Biovia Discovery Studio v4.5 was applied to assess the drug-likeness of Shikonin. The in vitro studies exposed that Shikonin shows an inhibitory potential against the PTP1B with an IC50 value of 15.51 µM. The kinetics studies revealed that it has a competitive inhibitory effect (Ki = 7.5 M) on the enzyme system, which could be useful in the production of preventive and therapeutic agents. The findings of this research suggested that the Shikonin could be used as an anti-diabetic agent and can be used as a novel source for drug delivery.
format Online
Article
Text
id pubmed-8271486
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82714862021-07-11 Assessment of Antidiabetic Activity of the Shikonin by Allosteric Inhibition of Protein-Tyrosine Phosphatase 1B (PTP1B) Using State of Art: An In Silico and In Vitro Tactics Saeed, Mohd Shoaib, Ambreen Tasleem, Munazzah Alabdallah, Nadiyah M. Alam, Md Jahoor Asmar, Zeina El Jamal, Qazi Mohammad Sajid Bardakci, Fevzi Alqahtani, Saad S. Ansari, Irfan Ahmad Badraoui, Riadh Molecules Article Diabetes mellitus is a multifactorial disease that affects both developing and developed countries and is a major public health concern. Many synthetic drugs are available in the market, which counteracts the associated pathologies. However, due to the propensity of side effects, there is an unmet need for the investigation of safe and effective drugs. This research aims to find a novel phytoconstituent having diminished action on blood glucose levels with the least side effects. Shikonin is a naturally occurring naphthoquinone dying pigment obtained by the roots of the Boraginaceae family. Besides its use as pigments, it can be used as an antimicrobial, anti-inflammatory, and anti-tumor agent. This research aimed to hypothesize the physicochemical and phytochemical properties of Shikonin’s in silico interaction with protein tyrosine phosphate 1B, as well as it’s in vitro studies, in order to determine its potential anti-diabetic impact. To do so, molecular docking experiments with target proteins were conducted to assess their anti-diabetic ability. Analyzing associations with corresponding amino acids revealed the significant molecular interactions between Shikonin and diabetes-related target proteins. In silico pharmacokinetics and toxicity profile of Shikonin using ADMET Descriptor, Toxicity Prediction, and Calculate Molecular Properties tools from Biovia Discovery Studio v4.5. Filter by Lipinski and Veber Rule’s module from Biovia Discovery Studio v4.5 was applied to assess the drug-likeness of Shikonin. The in vitro studies exposed that Shikonin shows an inhibitory potential against the PTP1B with an IC50 value of 15.51 µM. The kinetics studies revealed that it has a competitive inhibitory effect (Ki = 7.5 M) on the enzyme system, which could be useful in the production of preventive and therapeutic agents. The findings of this research suggested that the Shikonin could be used as an anti-diabetic agent and can be used as a novel source for drug delivery. MDPI 2021-06-30 /pmc/articles/PMC8271486/ /pubmed/34208908 http://dx.doi.org/10.3390/molecules26133996 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Saeed, Mohd
Shoaib, Ambreen
Tasleem, Munazzah
Alabdallah, Nadiyah M.
Alam, Md Jahoor
Asmar, Zeina El
Jamal, Qazi Mohammad Sajid
Bardakci, Fevzi
Alqahtani, Saad S.
Ansari, Irfan Ahmad
Badraoui, Riadh
Assessment of Antidiabetic Activity of the Shikonin by Allosteric Inhibition of Protein-Tyrosine Phosphatase 1B (PTP1B) Using State of Art: An In Silico and In Vitro Tactics
title Assessment of Antidiabetic Activity of the Shikonin by Allosteric Inhibition of Protein-Tyrosine Phosphatase 1B (PTP1B) Using State of Art: An In Silico and In Vitro Tactics
title_full Assessment of Antidiabetic Activity of the Shikonin by Allosteric Inhibition of Protein-Tyrosine Phosphatase 1B (PTP1B) Using State of Art: An In Silico and In Vitro Tactics
title_fullStr Assessment of Antidiabetic Activity of the Shikonin by Allosteric Inhibition of Protein-Tyrosine Phosphatase 1B (PTP1B) Using State of Art: An In Silico and In Vitro Tactics
title_full_unstemmed Assessment of Antidiabetic Activity of the Shikonin by Allosteric Inhibition of Protein-Tyrosine Phosphatase 1B (PTP1B) Using State of Art: An In Silico and In Vitro Tactics
title_short Assessment of Antidiabetic Activity of the Shikonin by Allosteric Inhibition of Protein-Tyrosine Phosphatase 1B (PTP1B) Using State of Art: An In Silico and In Vitro Tactics
title_sort assessment of antidiabetic activity of the shikonin by allosteric inhibition of protein-tyrosine phosphatase 1b (ptp1b) using state of art: an in silico and in vitro tactics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271486/
https://www.ncbi.nlm.nih.gov/pubmed/34208908
http://dx.doi.org/10.3390/molecules26133996
work_keys_str_mv AT saeedmohd assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT shoaibambreen assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT tasleemmunazzah assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT alabdallahnadiyahm assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT alammdjahoor assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT asmarzeinael assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT jamalqazimohammadsajid assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT bardakcifevzi assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT alqahtanisaads assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT ansariirfanahmad assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics
AT badraouiriadh assessmentofantidiabeticactivityoftheshikoninbyallostericinhibitionofproteintyrosinephosphatase1bptp1busingstateofartaninsilicoandinvitrotactics